I like your idea, but I don't think for one minute that the BOD should be applauded for taking the only choice they had left, which was a Hail Mary to international for covid. As I believe NP said, there aren't enough severe/critical patients left in the US to really enroll quickly in a trial, and they need to move quickly.

If the numbers in the Brazil trial(s) show the proper P value, the US FDA will be onboard, no doubt. It may be a bit too little too late for the US, but in the end, you give the FDA the numbers they want and you are undeniable. CYDY, to this point, has been...deniable, for whatever reason you want to choose.

There was no "stick handle strategy" employed by CYDY, there was "Oh crap, the numbers weren't what we thought they'd be at the end of the US trial, so what options do we have left?"

Instead of anyone just childishly giving this post a thumbs down, I'd rather you use your words and explain to me why you think perhaps I might be incorrect in my assessment. I am open to intelligent people holding an opposing point of view.